GNCA vs. SCPS, ARDS, NAVB, EVLO, SEEL, CMRA, AMPE, CALA, EFTR, and ATNFW
Should you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Seelos Therapeutics (SEEL), Comera Life Sciences (CMRA), Ampio Pharmaceuticals (AMPE), Calithera Biosciences (CALA), eFFECTOR Therapeutics (EFTR), and 180 Life Sciences (ATNFW). These companies are all part of the "pharmaceutical products" industry.
Genocea Biosciences vs.
Genocea Biosciences (NASDAQ:GNCA) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability.
Scopus BioPharma's return on equity of 0.00% beat Genocea Biosciences' return on equity.
Genocea Biosciences received 386 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 56.73% of users gave Genocea Biosciences an outperform vote.
Scopus BioPharma has lower revenue, but higher earnings than Genocea Biosciences.
Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.21, suggesting that its share price is 121% less volatile than the S&P 500.
In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.
0.6% of Genocea Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Scopus BioPharma beats Genocea Biosciences on 5 of the 9 factors compared between the two stocks.
Get Genocea Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genocea Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:GNCA) was last updated on 1/21/2025 by MarketBeat.com Staff
